Lotus Pharmaceutical , Ltd. EBIT

Lotus Pharmaceutical , Ltd. (1795.TW) currently reports a EBIT of $7.4B as of June 2026. That compares with $6.5B in the prior-year period — up 12.8% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Lotus Pharmaceutical , Ltd.'s EBIT history and peer comparisons.

Lotus Pharmaceutical , Ltd.'s EBIT increased from $6.5B to $7.4B — a 12.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lotus Pharmaceutical , Ltd.'s EBIT of $7.4B is lower than the its sector sector average of $2.6T. That is roughly 99.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Lotus Pharmaceutical , Ltd. reported $7.4B in EBIT as of June 2026. That compares with $6.5B in the prior-year period — up 12.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $7.4B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Lotus Pharmaceutical , Ltd., and consider following 1795.TW for alerts when major investors trade the stock.